Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 3,102	$ 1,676
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	813	116
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,289	$ 1,560